Navigation Links
Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
Date:12/9/2013

SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55th Annual ASH Conference in New Orleans, with data highlighting the Company's lead drug candidate, quizartinib. 

Results of the Phase 2b Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML): The purpose of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib.

This preliminary analysis is based on data available through May 28, 2013 with a minimum of eight weeks of follow up since the last subject first visit.  A total of 76 patients were enrolled from May 21, 2012 to March 27, 2013.  Median age for all patients was 55 (19-77) and 92% were FLT3-ITD(+).  35 patients remained in follow-up at the time of the analysis, and are currently censored for overall survival.  The following key information was presented:

For dose of 30mg:

  • The CRc rate was 47 percent (5 percent CR+CRp, 42 percent CRi)
  • The rate of HSCT after quizartinib use was 32 percent
  • The median overall survival was 20.7 weeks, with 16/38 patients censored as they remained in follow-up at the time of the analysis
  • Of the 12 patients who were bridged to HSCT, the median overall survival was 31 weeks
  • Grade 2 or greater QT prolongation was 11%, with a 5% grade 3 rate and no grade 4 events
  • For dose of 60mg:

  • The
    '/>"/>

  • SOURCE Ambit Biosciences
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
    2. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
    3. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
    4. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
    5. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
    6. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
    7. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
    8. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
    9. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
    10. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
    11. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/17/2014)... Oct. 17, 2014 Research and ... "Research and Development Prospect of China Dialysis Market, ... Based on the 2013 version, this update ... about dialysis industry and the relevant effect in ... dialysis industry segmentations. Moreover, it analyzes Chinese private-owned ...
    (Date:10/17/2014)... BALTIMORE, Md. , Oct. 17, 2014 /PRNewswire-USNewswire/ ... Center for Medical Technology Policy: The ... from the FDA, public and private payers, medical ... representatives, clinicians, and other experts January 12, 2015 ... effectiveness and value of weight loss treatments.  Participants ...
    (Date:10/17/2014)... 2014  China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... received approval from the China Food and Drug ... prothrombin complex concentrate ("PCC") at its Shandong Taibang ... factor production facility for Good Manufacturing Practices ("GMP") ...
    Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
    (Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
    (Date:10/20/2014)... Akron, OH (PRWEB) October 20, 2014 ... new Assisted Living Center on Oct. 14. The $11 ... amenities and services, and a cooked-to-order kitchen with full-service ... forward Akron’s premier choice for first class Assisted Living ... groundbreaking. “Our residents deserve the highest quality of care ...
    (Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
    (Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
    (Date:10/20/2014)... (PRWEB) October 20, 2014 It’s hard to ... many orphans and vulnerable children around the world, it’s a ... some people, many children are forced to walk barefoot on ... their families or play with their friends. , Buckner ... with Air1 Radio in October to encourage support ...
    Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
    ... 5 (HealthDay News) -- Simple precautions will help keep you ... the house for winter or put up holiday decorations, experts ... people were treated in U.S. emergency departments for holiday decorating-related ... 43 percent of those injuries were caused by falls from ...
    ... find out whether a new drug or treatment makes ... life, according to a commentary published online December 3rd ... . Instead, most trials now are designed to detect ... which may not be clinically meaningful, write Alberto Ocana, ...
    ... Dec. 3 (HealthDay News) -- New research explains why immune function ... HIV. In those cases, the virus has mutations that protect ... kill immune cells, explained the researchers at the Mayo Clinic in ... not all HIV is equally bad for the immune system, the ...
    ... nicotine during pregnancy leads to a decrease in adult ... the hippocampus of the offspring, according to new research ... Neuroscience 2010, the annual Society for Neuroscience meeting in ... a possible cause for behavioral problems such as attention-deficit ...
    ... Dec. 3 (HealthDay News) -- The impending extinction of ... an important buffer against the transmission of infectious disease, ... the U.S. National Science Foundation and National Institutes of ... U.S. Environmental Protection Agency, focused on how the loss ...
    ... 2010 (BRONX, NY) Nearly a quarter of Americans ... cancer mortality rates than urban and suburban areas. Among the ... of physicians practice in rural areas and almost 4 out ... from an urban area. Finding the time, transportation, ...
    Cached Medicine News:Health News:Assessing positive outcomes of phase III trials 2Health News:Nicotine exposure in pregnant rats puts offspring at risk for learning disabilities 2Health News:Species Extinctions May Spell Trouble for Human Health 2Health News:ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA 2
    ... wide Mini-Sub cell GT system for ... acids in agarose gels includes a ... electrodes, a 15 x 7 cm ... two casting gates, and two 1.5 ...
    ... your data for future generations. Most gels can ... backing plate of our gel dryer, covering them ... over them to hold the cellophane flat. Tut's ... with an open area somewhat larger than the ...
    ... data for future generations. Most gels can be ... plate of our gel dryer, covering them with ... them to hold the cellophane flat. Tut's Tombs ... an open area somewhat larger than the gel ...
    ... Breeze Air Gel Dryer : Dry up to ... gels 8 10 cm without a vacuum ... drying, or no heat for controlled drying of ... dried gels. Add and remove gels at any ...
    Medicine Products: